Tag: celyad

November 7, 2016

Celyad's NKR-2 Phase I Safety Trial Delivers Encouraging Results

Celyad, a leader in the discovery and development of engineered cell therapies, today announces that first data analysis of the...
September 15, 2016

Celyad CEO to present at the 2016 Cell & Gene Meeting

Celyad, a leader in the discovery and development of engineered cell therapies, today announced that Dr. Christian Homsy, Chief Executive...
September 9, 2016

Celyad Completes NKR-2 Phase I Trial

Celyad today announced the successful completion of the 21-day safety follow-up of the last patient enrolled at the fourth dose...
February 25, 2016

Celyad Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial, Enrolls First Patient in the Third Dose Level

Celyad (NASDAQ:CYAD) announced the completion of the 21-day safety follow-up of the last patient enrolled in the second dose level...
February 19, 2016

Merus Announces $27 Million Bought Deal

Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) has entered into an agreement with a syndicate of underwriters co-led by...